Carsten Brunn has sold stock and made no open-market buys since Oct 2021

Carsten Brunn, Ph.D. is the President, Chief Executive Officer, and Chairman of the Board at Cartesian Therapeutics, Inc. (RNAC), a clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases, headquartered in Gaithersburg, Maryland.(

Brunn assumed leadership at Cartesian following its merger with Selecta Biosciences in November 2023, where he previously served as President and CEO since 2018.( Prior to Selecta, he held senior roles at Bayer, including President of Pharmaceuticals for the Americas Region (2017) and President of Bayer Pharmaceuticals in Japan (2013-2016), along with positions at Eli Lilly, Novartis, Basilea, and Bausch & Lomb across Europe, Asia, and the US.( He earned a Master of Science in Pharmaceutical Sciences from the University of Freiburg, a Ph.D. in Chemistry from the University of Hamburg, studied at the University of Washington, and completed executive education at London Business School.(

Written by Perplexity from public sources.